Cite
HARVARD Citation
Niu, J. et al. (2017). Parent‐Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients With BRCA 1/2–Mutated Cancer or PARP‐Sensitive Tumor Types. Journal of clinical pharmacology. pp. 977-987. [Online].